Physiologically‐Based Pharmacokinetic Model‐Informed Labeling for Cariprazine Drug Interactions With CYP3A Inhibitors [PDF]
CPT: Pharmacometrics & Systems PharmacologyCariprazine is a potent D3‐preferring dopamine D3/D2 receptor partial agonist, a serotonin 5‐HT1A receptor partial agonist, and a serotonin 5‐HT2B receptor antagonist approved for the treatment of a variety of psychiatric disorders.
Md Mahbubul Huq Riad +3 more
doaj +3 more sources
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy [PDF]
Neuropsychiatric Disease and Treatment, 2018 Leslie Citrome Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA Abstract: Cariprazine is an oral antipsychotic approved in the US and EU for the treatment of schizophrenia.
Leslie Citrome
exaly +4 more sources
Case Report: Long-Acting Oral Cariprazine [PDF]
Frontiers in Psychiatry, 2022 IntroductionCariprazine is a third-generation antipsychotic, approved for the treatment of schizophrenia and bipolar disorder and used off-label for schizoaffective disorder and treatment-resistant depression. Cariprazine is a partial agonist at dopamine
Emanuela Dyrmishi +7 more
doaj +3 more sources
Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy [PDF]
Advances in Therapy, 2013 Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist in late-stage clinical development for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the ...
Leslie Citrome
exaly +2 more sources
Real-World Disability Outcomes Among Patients Treated with Cariprazine vs Other Atypical Antipsychotics as Adjunctive Treatment for Major Depressive Disorder [PDF]
ClinicoEconomics and Outcomes ResearchPrakash S Masand,1 Mousam Parikh,2 Jamie T Ta,2 Sally W Wade,3 Filmon Haile,2 Susannah Ripley,4 Enrico Zanardo,5 Colleen S Spencer,4 François Laliberté,4 Nadia Nabulsi2 1Duke-NUS, Singapore; 2AbbVie, North Chicago, IL, USA; 3Wade Outcomes Research and ...
Masand PS +9 more
doaj +2 more sources
Therapeutic Advances in Psychopharmacology, 2020 Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as ‘atypical’ second generation antipsychotics. Originally approved for acute and maintenance treatment of schizophrenia as well as for acute mania and mixed mania ...
Stephen M Stahl, Debbi Ann Morrissette
exaly +2 more sources
Update on schizophrenia and bipolar disorder: focus on cariprazine [PDF]
Neuropsychiatric Disease and Treatment, 2016 Rona Jeannie Roberts,1 Lillian Jan Findlay,2 Peggy L El-Mallakh,2 Rif S El-Mallakh1 1Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, 2School of Nursing ...
Roberts RJ +3 more
doaj +3 more sources
Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation [PDF]
Neuropsychiatric Disease and Treatment, 2019 Christoph U Correll,1–3 Rakesh Jain,4 Jonathan M Meyer,5 Antonia Periclou,6 Timothy Carrothers,6 Ágota Barabássy,7 Mehul Patel,8 Willie Earley91Department of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY ...
Correll CU +7 more
doaj +4 more sources
Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting [PDF]
Frontiers in Psychiatry, 2023 Real-world evidence fills in an important gap by providing data on the effectiveness and tolerability of new medications in everyday patients. In this data collection form a Spanish hospital, the effectiveness and tolerability of cariprazine were ...
Lluis Niell Galmes, Elmars Rancans
doaj +3 more sources
Efficacy and Clinical Relevance of Adjunctive Cariprazine Treatment in Patients with Major Depressive Disorder: Post Hoc Analyses from a Phase III Study [PDF]
Neuropsychiatric Disease and TreatmentGeorge I Papakostas,1 Prakash S Masand,2 Anita H Clayton,3 Vladimir Maletic4 ,† Julie L Adams,5 Ludmyla Rekeda,6 Manpreet Kaur Singh,7 Majid Kerolous8 1Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; 2Academic Medicine ...
Papakostas GI +7 more
doaj +2 more sources